PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors

J Clin Invest. 2022 Jun 15;132(12):e156821. doi: 10.1172/JCI156821.

Abstract

CD4+ Th cells play a key role in orchestrating immune responses, but the identity of the CD4+ Th cells involved in the antitumor immune response remains to be defined. We analyzed the immune cell infiltrates of head and neck squamous cell carcinoma and colorectal cancers and identified a subset of CD4+ Th cells distinct from FOXP3+ Tregs that coexpressed programmed cell death 1 (PD-1) and ICOS. These tumor-infiltrating lymphocyte CD4+ Th cells (CD4+ Th TILs) had a tissue-resident memory phenotype, were present in MHC class II-rich areas, and proliferated in the tumor, suggesting local antigen recognition. The T cell receptor repertoire of the PD-1+ICOS+ CD4+ Th TILs was oligoclonal, with T cell clones expanded in the tumor, but present at low frequencies in the periphery. Finally, these PD-1+ICOS+ CD4+ Th TILs were shown to recognize both tumor-associated antigens and tumor-specific neoantigens. Our findings provide an approach for isolating tumor-reactive CD4+ Th TILs directly ex vivo that will help define their role in the antitumor immune response and potentially improve future adoptive T cell therapy approaches.

Keywords: Cancer; Immunology; Immunotherapy; Oncology; T cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD4-Positive T-Lymphocytes
  • CD8-Positive T-Lymphocytes
  • Head and Neck Neoplasms* / pathology
  • Humans
  • Inducible T-Cell Co-Stimulator Protein
  • Lymphocytes, Tumor-Infiltrating
  • Programmed Cell Death 1 Receptor* / genetics

Substances

  • ICOS protein, human
  • Inducible T-Cell Co-Stimulator Protein
  • Programmed Cell Death 1 Receptor